The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience. - Olszewska-Szopa, Magdalena; Ożańska, Agnieszka; Ożański, Tomasz; Rybka, Justyna; Wróbel, Tomasz (Leukemia & Lymphoma, 2024)